Eli Lilly and Company reported new Phase 3 clinical trial data showing its experimental drug retatrutide induces significant weight loss in adults.
These results are critical as the pharmaceutical industry seeks next-generation treatments for obesity and Type 2 diabetes that can achieve results previously associated with surgical interventions.
According to data released this week, weight loss across three different dosages ranged from 19% to 28% [1]. Other trial reports indicate that the drug can induce weight loss of up to 28.3% over a period of 80 weeks [3]. Some reports further suggest the average weight loss in these trials was roughly 28% [2].
The trials focused on adults living with obesity or Type 2 diabetes to evaluate the efficacy of retatrutide as a treatment option. The drug is designed to target multiple hormones to regulate weight and blood sugar levels.
Dr. Tara Narula, ABC News chief medical correspondent, said the findings suggest a potent effect on weight reduction across the studied patient groups—a trend that continues the industry's shift toward multi-receptor agonists.
Eli Lilly developed retatrutide to improve upon existing weight-loss medications by targeting additional biological pathways. The company is positioning the drug as a more effective alternative for patients who do not respond sufficiently to first-generation weight-loss injections.
“Weight loss across three dosages ranged from 19% to 28%”
The emergence of retatrutide represents a shift toward 'triple-agonist' medications that target three different receptors rather than one or two. If these Phase 3 results hold, the drug could bridge the gap between traditional pharmacological treatments and bariatric surgery, potentially changing the standard of care for chronic obesity and Type 2 diabetes management.
